TY  - GEN
AU  - Gerber,David E
AU  - Camidge,D Ross
AU  - Morgensztern,Daniel
AU  - Cetnar,Jeremey
AU  - Kelly,Ronan J
AU  - Ramalingam,Suresh S
AU  - Spigel,David R
AU  - Jeong,Woondong
AU  - Scaglioni,Pier P
AU  - Zhang,Song
AU  - Li,Marilyn
AU  - Weaver,David T
AU  - Vaikus,Louis
AU  - Keegan,Mitchell
AU  - Horobin,Joanna C
AU  - Burns,Timothy F
TI  - Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer
SN  - 1872-8332
PY  - 2020///1230
KW  - Adenocarcinoma of Lung
KW  - drug therapy
KW  - Benzamides
KW  - therapeutic use
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Drug Resistance, Neoplasm
KW  - drug effects
KW  - Female
KW  - Focal Adhesion Protein-Tyrosine Kinases
KW  - antagonists & inhibitors
KW  - Follow-Up Studies
KW  - Humans
KW  - Lung Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Mutation
KW  - Prognosis
KW  - Prospective Studies
KW  - Proto-Oncogene Proteins p21(ras)
KW  - genetics
KW  - Pyrazines
KW  - Salvage Therapy
KW  - Sulfonamides
KW  - Survival Rate
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S
UR  - https://doi.org/10.1016/j.lungcan.2019.10.033
ER  -